How Advances in Artificial Intelligence May Transform Health Care
Artificial intelligence has the potential to transform health care.
The past few years have brought a sharp rise in digital health solutions, accelerated by the COVID-19 pandemic and other supporting factors. The rapid rollout of telemedicine, remote monitoring and other tools since 2020 has paved the way for ongoing innovation in health care technology.
In 2024–2025, generative AI further expanded what’s possible. As populations age across the United States and Europe and health care expenses continue to climb, controlling costs while maintaining or improving care quality has become a central priority for policymakers and health systems. This pressure is especially acute in the U.S., which spends significantly more per capita on health care than most other developed nations but European countries also face rising budgetary strains under publicly funded systems.
Against this backdrop, finding ways to enhance patient outcomes at lower cost has never been more critical. Looking ahead, AI advancements could deliver benefits that are difficult to fully anticipate today. By streamlining processes and reducing expenses, AI has the potential to make quality health care more accessible to more people.
While AI could touch many parts of the health care ecosystem, drug discovery and diagnostics appear poised for some of the most meaningful near-term progress.
Accelerating Drug Research and Development
One area already benefiting from AI is pharmaceutical research and development (R&D). AI contributed meaningfully to the rapid creation of COVID-19 vaccines, compressing what traditionally took many years into roughly one year in some cases.
Beyond vaccines, AI is showing promise in speeding up the broader drug development timeline, which has historically spanned years or even decades. By analyzing vast datasets and simulating molecular interactions, AI can help researchers identify promising compounds more quickly and efficiently.
A notable example came from Google DeepMind, which used AI to predict the three-dimensional structures of nearly all known proteins in biology , roughly 200 million proteins, including every protein in the human genome. These 3D structures serve as fundamental building blocks for understanding biological processes, from immune responses to disease mechanisms. The resulting open database has already supported new scientific breakthroughs, such as aiding the development of a promising new malaria vaccine that could help combat a disease responsible for hundreds of thousands of deaths worldwide each year.
AI can also improve later-stage development, including clinical trials. When combined with machine learning, AI models trained on historical trial data can help identify suitable patient participants, determine optimal dosing schedules and detect potential safety issues earlier. This could lead to more efficient, safer and ultimately more successful trials, lowering both costs and risks for developers while bringing effective treatments to patients faster.
Enhancing Diagnostics and Medical Imaging
The diagnostics field is another domain where AI is making rapid strides, particularly in radiology and medical imaging.
AI tools have begun to assist radiologists in interpreting X-rays, CT scans, and other images more efficiently, helping deliver faster and more consistent results. Beyond speed, some applications aim to maintain diagnostic accuracy while reducing radiation exposure for patients.
The pace of innovation is clearly visible in regulatory approvals. In the United States, the number of AI-enabled medical devices cleared by the Food and Drug Administration (FDA) has grown dramatically, from roughly a dozen a decade ago to hundreds in recent years. Similar momentum is building in Europe, where the European Medicines Agency (EMA) and national regulators are evaluating AI tools under evolving medical device regulations.
The Enduring Role of Human Expertise
Despite impressive progress, AI is unlikely to replace doctors or other health care professionals in the foreseeable future. Early concerns about widespread job losses in fields like radiology have not materialized. In fact, research suggests that experienced radiologists often outperform AI systems when interpreting complex medical images, especially in nuanced or rare cases.
Instead, AI appears best positioned as a supportive tool , augmenting human capabilities, reducing routine workload and allowing clinicians to focus on higher-value tasks such as patient consultation and complex decision-making.
A key limitation is data availability. Training reliable AI models requires enormous volumes of high-quality data, which can be scarce for rare diseases or diverse patient populations. This reinforces the continued importance of human oversight, clinical judgment and real-world validation.
Investment Considerations in AI-Driven Health Care
For investors, selectivity remains essential when evaluating opportunities in AI-related health care. Large, well-established pharmaceutical and medical technology companies with strong cash flows, robust R&D budgets and global scale may offer more defensive profiles and steadier earnings potential, even during periods of market volatility.
At the same time, several risks warrant attention:
Regulatory hurdles: Stringent approval processes in the U.S. (FDA) and Europe (EMA and MDR regulations) can slow innovation and increase development timelines.
Pricing pressures: Potential drug price controls or reimbursement policies could affect profitability.
Data privacy and security: With AI relying on vast patient datasets, compliance with strict rules such as the EU’s GDPR becomes critical. Cybersecurity threats to health data also represent an ongoing concern for providers and technology firms alike.
As with any investment theme, thorough research and diversification are important. AI in health care is still evolving and outcomes will depend on successful integration with existing medical practices.
If you’re considering how AI-driven health care opportunities might fit into your broader investment strategy , speaking with a financial advisor can provide personalized guidance tailored to your goals and risk tolerance.